Diabetic Retinopathy Treatment Market By Disease Type ( Proliferative Diabetic Retinopathy treatment (PDR), Non Proliferative Diabetic Retinopathy treatment (NDPR)), By Treatment ( Medicines,(Anti-VEGF therapy, Intraocular steroid injection), Laser Surgery, Vitrectomy ), By Treatment Providers( Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers ) Industry Trends, Estimation & Forecast, 2017-2025

Market Overview:

Diabetic retinopathy, also known as diabetic eye disease, is a common retinal complication that arises in diabetic patients due to the damage caused to the retina. It is a medical condition that can be controlled via treatment, but cannot be cured completely. In less severe cases, diabetic retinopathy can be treated with diabetes management, however, in severe cases laser treatment or surgery is required. Self-care treatment of diabetic retinopathy involves the regulation of blood glucose levels by consuming a well formulated diabetic diet. However, treatment via surgery includes procedures such as vitrectomy, laser coagulation, and laser surgery. In addition, medicated treatment involves the administration of anti-VEGF drugs and other steroidal drugs.

The global diabetic retinopathy treatment market is expected to witness growth in its size due to the surging prevalence of diabetes and rise in the number of geriatric populace around the world. However, the lack of skilled professionals, inadequate healthcare facilities, and presence of low-income groups in the developing economies is expected to create hurdles in the growth of diabetic retinopathy market. In terms of region, North America is expected to account for the maximum market share due to the rising incidences of diabetic retinopathy and huge investments in the healthcare sector. Being a consolidated market with intense competition, the market players are focusing on mergers & acquisitions and technological advancements as their main growth strategies.

The report provides detailed qualitative and quantitative analysis of the diabetic retinopathy treatment market. Market size and forecast in terms of value has been provided for the period – (2017-2025), for the segments namely disease type, treatment type, and treatment providers in each of the major regions.

Diabetic Retinopathy Treatment Market Segmentation

By Disease Type
• Proliferative Diabetic Retinopathy treatment (PDR)
• Non Proliferative Diabetic Retinopathy treatment (NDPR)

By Treatment Type

 • Medicines
o Anti-VEGF therapy
o Intraocular steroid injection
• Laser Surgery
• Vitrectomy

By Treatment Providers
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

By Geography

• North America
o U.S.
o Canada
o Mexico

• Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe

• Asia-Pacific
o China
o Japan
o India
o Korea
o Rest of APAC

• South America
o Brazil
o Rest of South America

• Rest of the World
o Middle East
o Africa

CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC desk research
1.1.2. ERC data synthesis
1.1.3. Data validation and market feedback
1.1.4. ERC data sources

CHAPTER 2. DIABETIC RETINOPATHY TREATMENT MARKET OVERVIEW
2.1. DIABETIC RETINOPATHY TREATMENT MARKET INTRODUCTION
2.2. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE AND GROWTH RATE, 2017-2025
2.2.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Growth Rate (%), (2017-2025)

CHAPTER 3. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET BY DISEASE TYPE, 2017-2025
3.1. PROLIFERATIVE DIABETIC RETINOPATHY TREATMENT (PDR)
3.2. NON PROLIFERATIVE DIABETIC RETINOPATHY TREATMENT (NDPR)
3.3. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE BY DISEASE TYPE, 2017-2025
3.3.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Share (%) By Disease type, 2017-2025
3.3.2. Proliferative Diabetic Retinopathy treatment (PDR) Market Revenue and Growth Rate, 2017-2025
3.3.3. Non Proliferative Diabetic Retinopathy treatment (NDPR) Market Revenue and Growth Rate, 2017-2025

Note: Similar information coverage has been provided for treatment type segment.

CHAPTER 4. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET BY TREATMENT PROVIDERS, 2017-2025
4.1. HOSPITALS
4.2. OPHTHALMIC CLINICS
4.3. AMBULATORY SURGICAL CENTERS
4.4. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE BY TREATMENT PROVIDERS, 2017-2025
4.4.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Share (%) By Treatment Providers, 2017-2025
4.4.2. Hospitals Market Revenue and Growth Rate, 2017-2025
4.4.3. Ophthalmic Clinics Market Revenue and Growth Rate, 2017-2025
4.4.4. Ambulatory Surgical Centers Market Revenue and Growth Rate, 2017-2025

CHAPTER 5. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET BY REGION, 2017-2025
5.1. NORTH AMERICA
5.1.1. U.S.
5.1.2. Canada
5.1.3. Mexico
5.2. EUROPE
5.2.1. U.K.
5.2.2. France
5.2.3. Germany
5.2.4. Italy
5.2.5. Spain
5.2.6. Rest of Europe
5.3. ASIA PACIFIC
5.3.1. China
5.3.2. Japan
5.3.3. India
5.3.4. Korea
5.3.5. Rest of APAC
5.4. SOUTH AMERICA
5.4.1. Brazil
5.4.2. Rest of South America
5.5. REST OF THE WORLD
5.5.1. Middle East
5.5.2. Africa
5.6. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET REVENUE BY REGION, 2017-2025
5.6.1. Global Diabetic Retinopathy Treatment Market Revenue (Million USD) and Share (%) By Region, 2017-2025
5.6.2. North America Market Revenue and Growth Rate, 2017-2025
5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
5.6.5. South America Market Revenue and Growth Rate, 2017-2025
5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

CHAPTER 6. MARKET DETERMINANTS
6.1. MARKET DRIVERS
6.2. MARKET RESTRAINTS
6.3. MARKET OPPORTUNITIES
6.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 7. GLOBAL DIABETIC RETINOPATHY TREATMENT MARKET COMPETITION BY SERVICE PROVIDERS
7.1. GLOBAL DIABETIC RETINOPATHY TREATMENT REVENUE AND SHARE BY SERVICE PROVIDERS (2017-2025)
7.1.1. Global Diabetic Retinopathy Treatment Revenue (Million USD) and Share (%) by Service Providers (2017-2025)
7.2. DIABETIC RETINOPATHY TREATMENT MARKET COMPETITIVE SITUATION AND TRENDS
7.2.1. Diabetic Retinopathy Treatment Market Share (%) of Top 3 Service Providers
7.2.2. Diabetic Retinopathy Treatment Market Share (%) of Top 5 Service Providers

CHAPTER 8. COMPANY PROFILES
8.1. AMPIO PHARMACEUTICALS, INC.
8.1.1. Business Overview
8.1.2. Company Basic Information
8.1.3. Diabetic Retinopathy Treatment Product Details
8.1.4. Ampio Pharmaceuticals, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.2. AERPIO PHARMACEUTICALS
8.2.1. Business Overview
8.2.2. Company Basic Information
8.2.3. Diabetic Retinopathy Treatment Product Details
8.2.4. Aerpio Pharmaceuticals Diabetic Retinopathy Treatment Revenue and Gross Margin
8.3. SIRNAOMICS, INC.
8.3.1. Business Overview
8.3.2. Company Basic Information
8.3.3. Diabetic Retinopathy Treatment Product Details
8.3.4. Sirnaomics, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.4. BAYER AG
8.4.1. Business Overview
8.4.2. Company Basic Information
8.4.3. Diabetic Retinopathy Treatment Product Details
8.4.4. Bayer AG Diabetic Retinopathy Treatment Revenue and Gross Margin
8.5. ALIMERA SCIENCES, INC.
8.5.1. Business Overview
8.5.2. Company Basic Information
8.5.3. Diabetic Retinopathy Treatment Product Details
8.5.4. Alimera Sciences, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.6. GENENTECH, INC.
8.6.1. Business Overview
8.6.2. Company Basic Information
8.6.3. Diabetic Retinopathy Treatment Product Details
8.6.4. Genentech, Inc. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.7. THROMBOGENICS
8.7.1. Business Overview
8.7.2. Company Basic Information
8.7.3. Diabetic Retinopathy Treatment Product Details
8.7.4. ThromboGenics Diabetic Retinopathy Treatment Revenue and Gross Margin
8.8. NOVARTIS AG
8.8.1. Business Overview
8.8.2. Company Basic Information
8.8.3. Diabetic Retinopathy Treatment Product Details
8.8.4. Novartis AG Diabetic Retinopathy Treatment Revenue and Gross Margin
8.9. KOWA COMPANY LTD.
8.9.1. Business Overview
8.9.2. Company Basic Information
8.9.3. Diabetic Retinopathy Treatment Product Details
8.9.4. Kowa Company Ltd. Diabetic Retinopathy Treatment Revenue and Gross Margin
8.10. ALLERGAN PLC (ACTAVIS PLC)
8.10.1. Business Overview
8.10.2. Company Basic Information
8.10.3. Diabetic Retinopathy Treatment Product Details
8.10.4. Allergan PLC (Actavis PLC) Diabetic Retinopathy Treatment Revenue and Gross Margin

CHAPTER 9. DIABETIC RETINOPATHY TREATMENT MARKET VALUE CHAIN ANALYSIS
9.1. DIABETIC RETINOPATHY TREATMENT INDUSTRIAL CHAIN ANALYSIS
9.2. CONSUMER ANALYSIS
9.2.1. Consumer 1
9.2.2. Consumer 2
9.2.3. Consumer 3
9.2.4. Consumer 4

• Ampio Pharmaceuticals, Inc.
• Aerpio Pharmaceuticals
• Sirnaomics, Inc.
• Bayer AG
• Alimera Sciences, Inc.
• Genentech, Inc.
• ThromboGenics
• Novartis AG
• Kowa Company Ltd.
• Allergan PLC (Actavis PLC)
• BCN Peptides S.A.
• Regeneron Pharmaceuticals, Inc.